CS
ELVN icon

Candriam SCA’s Enliven Therapeutics ELVN Stock Holding History

Candriam SCA’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9M Buy
905,674
+311,595
+52% +$13.2M 0.21% 103
2026
Q1 		$23.3M Buy
594,079
+141,060
+31% +$3.91M 0.12% 173
2025
Q4 		$6.98M Sell
453,019
-156,333
-26% -$3.11M 0.03% 322
2025
Q3 		$12.5M Buy
609,352
+192,702
+46% +$3.88M 0.07% 242
2025
Q2 		$8.36M Buy
+416,650
New +$7.89M 0.05% 274

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Candriam SCA's ELVN Position: Q2 2026 in Review

Candriam SCA increased its Enliven Therapeutics (ELVN) stake by 52% in Q2 2026, buying an estimated $13.2M and bringing the position to 905,674 shares worth $45.9M. The position accounts for 0.21% of the portfolio, ranked #103.

Candriam SCA first reported a position in ELVN in Q2 2025 and has held it in 5 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Candriam SCA held 905,674 shares of Enliven Therapeutics worth $45.9M as of Q2 2026.
  • Candriam SCA bought 311,595 Enliven Therapeutics shares in Q2 2026, an estimated $13.2M.
  • Enliven Therapeutics made up 0.21% of Candriam SCA's portfolio in Q2 2026, its #103 holding.
  • Candriam SCA first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.